
PAASPort®
A tool to judge risk of bias in biomedical research
Identify potential sources of bias early and improve decision-making.

START YOUR JOURNEY TO ACCREDITATION
by getting detailed information about PAASPort®

Risks in early-stage biotech investment
As the recent cases illustrate, apparent or actual issues with data integrity and research rigor can damage not only reputation of individual scientists but also affect the value of companies, whether privately held or publicly traded.
PAASP introduces a new service for the investment community engaged in early-stage biotech:
PAASPort®-based assessment of investment opportunities for data integrity and research rigor risks.
PAASP NETWORK PARTNERS ARE SUPPORTED BY
Funder of EQIPD from the Innovative Medicines Initiative 2 Joint Undertaking.
Conferrer of the NIDA Challenge Award and SBIR Grant for PAASPort®.
United States sponsor of the Global Preclinical Data Forum and sponsor of the Negative Data Prize and PEERS project.
PARTNER ORGANIZATIONS
A taste of our most recent headlines.
“Publication of negative/null results discussed at NIH”
November 2, 2022NINDS Office of Research Quality has presented a proposal on how to address the publication bias. It can be watched HERE (starts at…
Read More“The customer is king!”
November 2, 2022Once during our vacation in Greece, our children asked for ice cream after having dinner. When the waiter was asked about…
Read More“Hold your horses!”
November 2, 2022Risk of Alzheimer’s disease nearly doubles in older adults with Covid-19! Like many of you, several weeks ago we have also…
Read More